Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-801 in Obesity (MOMENTUM)
NCT05295875Phase 2Completed
- Sponsor
- Altimmune, Inc.
- Start
- Mar 2022
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pemvidutide in obesity, Overweight, sponsored by Altimmune, Inc.. Started Mar 2022; status: completed.
02
Drugs
pemvidutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05295875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295875.